Amedisys Inc (AMED)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-9,747	2,648	2,330	112,184	118,609	120,939	140,303	190,873	209,072	220,125	247,100	201,625	183,557	166,157	128,276	127,302	126,800	126,600	123,900	123,500
Total stockholders’ equity	US$ in thousands	1,066,510	1,039,910	1,006,780	1,079,120	1,051,570	1,015,740	985,646	966,758	931,351	905,264	874,272	788,153	809,224	756,205	720,851	679,197	640,450	602,564	561,781	520,246
ROE		-0.91%	0.25%	0.23%	10.40%	11.28%	11.91%	14.23%	19.74%	22.45%	24.32%	28.26%	25.58%	22.68%	21.97%	17.80%	18.74%	19.80%	21.01%	22.05%	23.74%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-9,747K ÷ $1,066,510K
= -0.91%

Amedisys Inc.'s return on equity (ROE) has shown a decreasing trend over the past few quarters. In Q4 2023, the ROE was negative at -0.91%, indicating that the company's net income was insufficient to cover shareholders' equity. This was a significant drop from the previous quarter's positive ROE of 0.25%.

Compared to the same quarter the previous year, there has been a substantial decline in ROE. In Q4 2022, the ROE was 11.28%, indicating a steep decrease to the negative territory in Q4 2023.

The ROE for Amedisys Inc. in Q2 and Q3 2022 was relatively higher at 14.23% and 11.91% respectively, showing a more favorable performance compared to the recent quarters. However, the ROE has been on a declining trend since then.

Overall, the negative ROE in Q4 2023 raises concerns about the company's profitability and efficiency in generating returns for its shareholders. Amedisys Inc. may need to focus on improving its earnings and cost management to enhance its ROE performance in the future.